ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 274 filers reported holding ARRAY BIOPHARMA INC in Q1 2019. The put-call ratio across all filers is 0.24 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $5,504,000 | +90.1% | 118,800 | 0.0% | 0.05% | +85.7% |
| Q1 2019 | $2,896,000 | +71.1% | 118,800 | 0.0% | 0.03% | +47.4% |
| Q4 2018 | $1,693,000 | -6.3% | 118,800 | 0.0% | 0.02% | +18.8% |
| Q3 2018 | $1,806,000 | -9.4% | 118,800 | 0.0% | 0.02% | -23.8% |
| Q2 2018 | $1,993,000 | +2.8% | 118,800 | 0.0% | 0.02% | +5.0% |
| Q1 2018 | $1,939,000 | -17.0% | 118,800 | -34.9% | 0.02% | -16.7% |
| Q4 2017 | $2,336,000 | +4.1% | 182,500 | 0.0% | 0.02% | -4.0% |
| Q3 2017 | $2,245,000 | +46.9% | 182,500 | 0.0% | 0.02% | +38.9% |
| Q2 2017 | $1,528,000 | -6.0% | 182,500 | +0.3% | 0.02% | -5.3% |
| Q1 2017 | $1,626,000 | +1.1% | 181,870 | -0.6% | 0.02% | -5.0% |
| Q4 2016 | $1,608,000 | +91.0% | 182,900 | +46.7% | 0.02% | +81.8% |
| Q3 2016 | $842,000 | +293.5% | 124,700 | +107.1% | 0.01% | +266.7% |
| Q2 2016 | $214,000 | +2575.0% | 60,200 | +2129.6% | 0.00% | – |
| Q1 2016 | $8,000 | – | 2,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Redmile Group, LLC | 16,618,776 | $146,079,000 | 12.59% |
| BVF INC/IL | 4,986,186 | $43,829,000 | 8.81% |
| First Light Asset Management, LLC | 1,000,361 | $8,793,000 | 3.86% |
| Crosspoint Capital Strategies, LLC | 463,005 | $4,070,000 | 3.62% |
| Consonance Capital Management LP | 2,723,471 | $23,912,000 | 2.63% |
| KOPP INVESTMENT ADVISORS LLC | 219,926 | $1,933,000 | 2.04% |
| SPHERA FUNDS MANAGEMENT LTD. | 900,000 | $7,911,000 | 2.00% |
| Orbimed Advisors | 16,088,800 | $141,421,000 | 1.80% |
| Cormorant Asset Management, LP | 1,150,000 | $10,109,000 | 1.36% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 2,073,680 | $18,227,000 | 1.26% |